Inovio Pharma (INO)

$7.74 0.22 (2.93%)

19:59 EDT INO Stock Quote Delayed 20 Minutes

Volume:

Previous Close $7.74

Market Cap 704.05M

PE Ratio -6.79

EPS -1.14

Volume (Avg. Vol.) 11.05M

Day's Range 7.24 - 7.94

52-Week Range 1.92 - 19.36

Dividend & Yield N/A (N/A)

INO Stock Predictions, Articles, and Inovio Pharma News

From InvestorPlace
From the Web

Buying INO Stock Right Now Is More a Bet Than an Investment

By Chris Markoch Apr 2, 2020

Ino stock has brought its COVID-19 vaccine to trial in record time. But for the stock to move higher, it needs to get the product to market.

Look For Better Buys Than Coronavirus Play INO Stock

By Thomas Niel Mar 30, 2020

Biotech investing is tough. If you have a background in this space, sure, knock yourself out. But if you are an investor looking for solid opportunities, look elsewhere, and avoid INO stock. As the overall market recovers, there are plenty of other screaming buys to consider.

Inovio Pharmaceuticals Will Fall Once Coronavirus Fears Fade

By Ian Bezek, InvestorPlace Contributor Mar 26, 2020

INO stock has moved higher based on Inovio's hunt for a coronavirus vaccine. But this race also makes the pharmaceutical firm a one-dimensional investment.

10 Stocks to Buy as They Ride a Coronavirus Tailwind

By Josh Enomoto, InvestorPlace Contributor Mar 24, 2020

With pandemic fears shuttering many economies, most investments have cratered. However, a small group of coronavirus stocks may offer significant upside potential.

Inovio Is Still Hot as the Coronavirus Spreads

By Chris Lau, InvestorPlace Contributor Mar 24, 2020

INO stock still has some serious upside, thanks to its INO-4800. Inovio's coronavirus vaccine takes the lead and is in preclinical trials.

Inovio Could Be a Bargain Using Probability Analysis

By Mark R. Hake, CFA Mar 24, 2020

Inovio could be a bargain using probability analysis. INO stock is cheap if there is a greater than 5% chance its COVID-19 vaccine will be successful.

Compare Brokers

Inovio Rise is Today’s Sign of the Stockocalypse

By Dana Blankenhorn, InvestorPlace Contributor Mar 24, 2020

Inovio has a coronavirus vaccine candidate that has just entered testing, and INO stock speculators are going mad over it.

Can Inovio’s Vaccine Efforts Maintain Growth for INO Stock?

By Brad Moon, InvestorPlace Contributor Mar 23, 2020

Once an afterthought in the pharmaceutical space, INO stock suddenly looks interesting amid the coronavirus pandemic. However, it could also be a very temporary tailwind.

As the Coronavirus Worsens, INO Stock Gets More Interesting

By Josh Enomoto, InvestorPlace Contributor Mar 16, 2020

Gambling on a single vaccine play is always risky. However, INO stock may have substance given that the coronavirus could get a lot worse.

Inovio Stock Is Still Too Volatile Despite Grant Support for Vaccine

By David Moadel Mar 16, 2020

Inovio may look promising as a contender in the race to develop a vaccine, but INO stock is still very risky. Here's what to look out for.

INO Stock Is a Purely Speculative COVID-19 Vaccine Play

By Faisal Humayun Mar 12, 2020

The timeline to develop the vaccine seems unrealistic. Further, clinical trials will provide credibility to claims.

Don’t Buy Inovio Stock on Hopes for a Vaccine

By Luke Lango, InvestorPlace Markets Analyst Mar 12, 2020

Coronavirus hysteria on Wall Street is temporary. When it passes, INO stock could turn into a "look out below" situation.

Compare Brokers

Stock Market Today: Stocks Hit Panic Point, Trigger Trading Halt

By Bret Kenwell, InvestorPlace Contributor Mar 9, 2020

Oil prices plunged more than 33% at one point, while stock trading was temporarily halted. Here's what happened in the stock market today.

Race to Respond to Coronavirus Threat a Boon for Inovio Stock

By Ian Cooper Mar 9, 2020

As the world races for a coronavirus vaccine, Inovio remains one of the top “must own” stocks. If it sees success in human trials and can begin delivery of its vaccine this year, I wouldn’t be shocked to see shares of INO closer to $20 a share.

Is Inovio Pharmaceuticals Stock the Cure for Your Portfolio?

By Chris Tyler, InvestorPlace Contributor Mar 9, 2020

Inovio Pharmaceuticals continues to rally on COVID-19 vaccine hopes, but overbought conditions and key challenges still make INO stock a risky proposition.